|
Synonyms
|
TNFRSF11B, Osteoclastogenesis Inhibitory Factor, Tumor Necrosis Factor Receptor Superfamily Member 11B
|
|
Species
|
Human
|
|
Accession
|
O00300
|
|
GeneID
|
4982
|
|
Source
|
Escherichia coli.
|
|
Molecular Weight
|
重组人骨保护素蛋白Approximately 19.7 kDa, a single non-glycosylated polypeptide chain containing 173 amino acids.
|
|
Quantity
|
10µg/50µg/1000µg
|
|
AA Sequence
|
ETFPPKYLHY DEETSHQLLC DKCPPGTYLK QHCTAKWKTV CAPCPDHYYT DSWHTSDECL YCSPVCKELQ YVKQECNRTH NRVCECKEGR YLEIEFCLKH RSCPPGFGVV QAGTPERNTV CKRCPDGFFS NETSSKAPCR KHTNCSVFGL LLTQKGNATH DNICSGNSES TQK
|
|
Purity
|
> 95 % by SDS-PAGE and HPLC analyses.
|
|
Biological Activity
|
Fully biologically active when compared to standard. The ED50 as determined by neutralizing the stimulation of U937 cells is less than 10 ng/ml, corresponding to a specific activity of > 1.0 × 105 IU/mg in the presence of 10 ng/mL soluble rHuRANKL (sRANKL).
|
|
Physical Appearance
|
重组人骨保护素蛋白Sterile Filtered White lyophilized (freeze-dried) powder.
|
|
Formulation
|
Lyophilized from a 0.2 μm filtered concentrated solution in 20 mM PB,150 mM NaCl, pH 6.0.
|
|
Endotoxin
|
Less than 1 EU/μg of rHuOPG as determined by LAL method.
|
|
Reconstitution
|
We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/ml. Stock solutions should be apportioned into working aliquots and stored at ≤ -20°C. Further dilutions should be made in appropriate buffered solutions.
|
|
Storage
|
重组人骨保护素蛋白This lyophilized preparation is stable at 2-8 °C, but should be kept at -20 °C for long term storage, preferably desiccated. Upon reconstitution, the preparation is stable for up to one week at 2-8 °C. For maximal stability, apportion the reconstituted preparation into working aliquots and store at -20 °C to -70 °C. Avoid repeated freeze/thaw cycles.
|
|
重组人骨保护素蛋白
|
|
|
SDS-PAGE
|
|
|
Reference
|
1. Simonet WS, Lacey DL, Dunstan CR, et al. 1997. Cell. 89:309-19.
2. Schoppet M, Preissner KT, Hofbauer LC. 2002. Arterioscler Thromb Vasc Biol. 22:549-53.
3. Tsuda E, Goto M, Mochizuki S, et al. 1997. Biochem Biophys Res Commun. 234:137-42.
4. Luan X, Lu Q, Jiang Y, et al. 2012. J Immunol. 189:245-52.
|
|
Background
|
Osteoprotegerin (OPG), also named osteoclastogenesis inhibitory factor (OCIF), and tumor necrosis factor receptor superfamily member 11B (TNFRSF11B), is a TNFRSF11B-encoded protein in humans. OPG is a 401 a.a. basic glycoprotein which comprises 7 structural domains. It is either a 60 kDa monomer or a 120 kDa dimer linked by disulfide bridges. OPG acts as a decoy receptor for the receptor activator of nuclear factor kappa B ligand (RANKL) and inhibits the activation of osteoclasts and promotes osteoclast apoptosis in vitro and may also play a role in preventing arterial calcification. OPG has been applied to decrease bone resorption in women with postmenopausal osteoporosis and in patients with lytic bone metastases. Mature human OPG shares 86 %, 87 %, 92 %, 92 % and 88 % amino acid sequence identity with mouse, rat, equine, canine and bovine OPG, respectively.
|
